Roche Holding AG Net Long-Term Debt 2010-2024 | RHHBY
Roche Holding AG annual/quarterly net long-term debt history and growth rate from 2010 to 2024. Net long-term debt can be defined as the net amount of long term debt issued and repaid. This field is either calculated as the sum of the long term debt fields or used if a company does not report debt issued and repaid separately
- Roche Holding AG net long-term debt for the quarter ending December 31, 2024 was $0M, a 0% increase year-over-year.
- Roche Holding AG net long-term debt for the twelve months ending December 31, 2024 was $0M, a 0% increase year-over-year.
- Roche Holding AG annual net long-term debt for 2024 was $5.475B, a 23.39% decline from 2023.
- Roche Holding AG annual net long-term debt for 2023 was $7.147B, a 1.91% increase from 2022.
- Roche Holding AG annual net long-term debt for 2022 was $7.013B, a 43.97% increase from 2021.
Roche Holding AG Annual Net Long-Term Debt
(Millions of US $) |
| 2024 |
$5,475 |
| 2023 |
$7,147 |
| 2022 |
$7,013 |
| 2021 |
$4,871 |
| 2020 |
$N/A |
| 2019 |
$-5,449 |
| 2018 |
$102 |
| 2017 |
$-1,592 |
| 2016 |
$-840 |
| 2015 |
$-1,452 |
| 2014 |
$3,004 |
| 2013 |
$-7,160 |
| 2012 |
$-1,737 |
| 2011 |
$N/A |
| 2010 |
$N/A |
| 2009 |
$N/A |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$255.245B |
$68.726B |
|
Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.
|
